ロード中...
Added Benefit of Raxibacumab to Antibiotic Treatment of Inhalational Anthrax
Although antibiotics treat bacteremia in inhalational anthrax, pathogenesis is mainly driven by bacterial exotoxins. Raxibacumab, an IgG1 monoclonal antibody, binds the protective antigen (PA) of Bacillus anthracis, thus blocking toxin effects and leading to improved survival in the rabbit and monke...
保存先:
| 出版年: | Antimicrob Agents Chemother |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4335881/ https://ncbi.nlm.nih.gov/pubmed/25487792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.04606-14 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|